EQUALINE

Product NDC: 41163-163
11-digit product format: 411630163
Labeler code: 41163
Product ID: 41163-163_db1dcc82-960e-4390-b951-bd0a3b81b550
Type: HUMAN OTC DRUG
Nonproprietary name: TRICLOSAN
Dosage form: LIQUID
Route: TOPICAL
Labeler: SUPERVALU INC.
Application: part333E
Marketing category: OTC MONOGRAPH NOT FINAL
Marketing start: 2012-06-26
Marketing end: 0000-00-00
Substance: TRICLOSAN
Active strength: 0 mg/100mL
NDC exclude flag: E
Listing certified through: 2018-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 4 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	41163-163		I	Inactivated by FDA	2026-10-05
excluded product	product	41163-163		I	Inactivated by FDA	2026-10-05
excluded package	package	41163-163	41163-163-32	I	Inactivated by FDA	2026-10-05
excluded package	package	41163-163	41163-163-08	I	Inactivated by FDA	2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 2 · 88 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	41163-163-32	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	41163-163-08	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	41163-163-32	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	41163-163-08	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	41163-163-32	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	41163-163-08	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	41163-163-32	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	41163-163-08	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	41163-163-32	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	41163-163-08	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	41163-163-32	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	41163-163-08	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	41163-163-32	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	41163-163-08	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	41163-163-32	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	41163-163-08	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	41163-163-32	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	41163-163-08	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	41163-163-32	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	41163-163-08	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	41163-163-32	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	41163-163-08	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	41163-163-32	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	41163-163-08	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	41163-163-32	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	41163-163-08	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	41163-163-32	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	41163-163-08	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	41163-163-32	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	41163-163-08	`1332a3947898…`	`d4bfe170f9cd…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
41163-163-08	2020-01-31	C162847	48780-1	9d75b9d0-3f43-f424-e053-dadaa90a57ce	DRUG FACTS
41163-163-32	2020-01-31	C162847	48780-1	9d75b9d0-3f40-f424-e053-dadaa90a57ce	DRUG FACTS

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
41163-163-08	EQUALINE	221 mL in 1 BOTTLE, PUMP	LIQUID	221		1
41163-163-32	EQUALINE	946 mL in 1 BOTTLE, PLASTIC	LIQUID	946		1

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
TRICLOSAN	ACTIVE INGREDIENT	4NM5039Y5X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
TRICLOSAN	ACTIVE INGREDIENT	4NM5039Y5X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
TRICLOSAN	ACTIVE MOIETY	4NM5039Y5X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
TRICLOSAN	ACTIVE MOIETY	4NM5039Y5X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
ALOE VERA LEAF	INACTIVE INGREDIENT	ZY81Z83H0X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
ALOE VERA LEAF	INACTIVE INGREDIENT	ZY81Z83H0X	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
AMMONIUM LAURYL SULFATE	INACTIVE INGREDIENT	Q7AO2R1M0B	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
AMMONIUM LAURYL SULFATE	INACTIVE INGREDIENT	Q7AO2R1M0B	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
CETYL ALCOHOL	INACTIVE INGREDIENT	936JST6JCN	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
CETYL ALCOHOL	INACTIVE INGREDIENT	936JST6JCN	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
COCAMIDOPROPYL BETAINE	INACTIVE INGREDIENT	5OCF3O11KX	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
COCAMIDOPROPYL BETAINE	INACTIVE INGREDIENT	5OCF3O11KX	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
D&C YELLOW NO. 10	INACTIVE INGREDIENT	35SW5USQ3G	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
D&C YELLOW NO. 10	INACTIVE INGREDIENT	35SW5USQ3G	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
DIPROPYLENE GLYCOL	INACTIVE INGREDIENT	E107L85C40	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
DIPROPYLENE GLYCOL	INACTIVE INGREDIENT	E107L85C40	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
FD&C GREEN NO. 3	INACTIVE INGREDIENT	3P3ONR6O1S	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
FD&C GREEN NO. 3	INACTIVE INGREDIENT	3P3ONR6O1S	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
METHYLPARABEN	INACTIVE INGREDIENT	A2I8C7HI9T	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
METHYLPARABEN	INACTIVE INGREDIENT	A2I8C7HI9T	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
POLYQUATERNIUM-10 (400 CPS AT 2%)	INACTIVE INGREDIENT	HB1401PQFS	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
POLYQUATERNIUM-10 (400 CPS AT 2%)	INACTIVE INGREDIENT	HB1401PQFS	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
PROPYLPARABEN	INACTIVE INGREDIENT	Z8IX2SC1OH	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
PROPYLPARABEN	INACTIVE INGREDIENT	Z8IX2SC1OH	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM PHOSPHATE	INACTIVE INGREDIENT	SE337SVY37	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM PHOSPHATE	INACTIVE INGREDIENT	SE337SVY37	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM PYRROLIDONE CARBOXYLATE	INACTIVE INGREDIENT	469OTG57A2	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM PYRROLIDONE CARBOXYLATE	INACTIVE INGREDIENT	469OTG57A2	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM XYLENESULFONATE	INACTIVE INGREDIENT	G4LZF950UR	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
SODIUM XYLENESULFONATE	INACTIVE INGREDIENT	G4LZF950UR	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
41163-163	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1	Legacy NDC, 1 package rows	20120705_e695edb2-21a7-4ece-8c49-efd4c487abc7.zip
41163-163	EQUALINE (TRICLOSAN) LIQUID [SUPERVALU INC.]	1	Legacy NDC, 1 package rows	20120709_547db2cb-0415-4def-ab3f-89871b504684.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
4NM5039Y5X	TRICLOSAN	3380-34-5	TRICLOSAN

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
1053855	triclosan 0.46 % Medicated Liquid Soap	PSN	547db2cb-0415-4def-ab3f-89871b504684	1
1053855	triclosan 0.46 % Medicated Liquid Soap	PSN	e695edb2-21a7-4ece-8c49-efd4c487abc7	1
1053855	triclosan 4.6 MG/ML Medicated Liquid Soap	SCD	547db2cb-0415-4def-ab3f-89871b504684	1
1053855	triclosan 4.6 MG/ML Medicated Liquid Soap	SCD	e695edb2-21a7-4ece-8c49-efd4c487abc7	1
1053855	triclosan 0.46 % Foaming Medicated Hand Soap	SY	547db2cb-0415-4def-ab3f-89871b504684	1
1053855	triclosan 0.46 % Foaming Medicated Hand Soap	SY	e695edb2-21a7-4ece-8c49-efd4c487abc7	1
1053855	triclosan 0.46 % Medicated Liquid Soap	SY	547db2cb-0415-4def-ab3f-89871b504684	1
1053855	triclosan 0.46 % Medicated Liquid Soap	SY	e695edb2-21a7-4ece-8c49-efd4c487abc7	1

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Status
41163-163-08	41163016308	221 mL in 1 BOTTLE, PUMP	221 ml	Historical
41163-163-32	41163016332	946 mL in 1 BOTTLE, PLASTIC	946 ml	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
DRUG FACTS	SUPERVALU INC. \| APOLLO HEALTH AND BEAUTY CARE	2012-07-04	HUMAN OTC DRUG LABEL	1
DRUG FACTS	SUPERVALU INC. \| APOLLO HEALTH AND BEAUTY CARE	2012-06-29	HUMAN OTC DRUG LABEL	1